Happy Thanksgiving! Save 50% on Your MarketBeat All Access Subscription.
  •  days
  •  Hours
  •  Minutes
  •  Seconds
×
QQQ   282.71 (-1.47%)
AAPL   144.22 (-2.63%)
MSFT   241.76 (-2.32%)
META   108.78 (-2.36%)
GOOGL   96.05 (-1.45%)
AMZN   93.95 (+0.58%)
TSLA   182.92 (+0.03%)
NVDA   158.27 (-2.72%)
NIO   10.12 (-0.49%)
BABA   75.88 (+0.50%)
AMD   73.19 (-2.60%)
T   18.82 (-1.57%)
MU   55.75 (-4.55%)
CGC   3.40 (-7.10%)
F   13.73 (-2.49%)
GE   85.47 (-3.03%)
DIS   95.69 (-3.22%)
AMC   7.33 (-2.40%)
PYPL   79.93 (-0.19%)
PFE   49.57 (+0.73%)
NFLX   281.17 (-1.53%)
QQQ   282.71 (-1.47%)
AAPL   144.22 (-2.63%)
MSFT   241.76 (-2.32%)
META   108.78 (-2.36%)
GOOGL   96.05 (-1.45%)
AMZN   93.95 (+0.58%)
TSLA   182.92 (+0.03%)
NVDA   158.27 (-2.72%)
NIO   10.12 (-0.49%)
BABA   75.88 (+0.50%)
AMD   73.19 (-2.60%)
T   18.82 (-1.57%)
MU   55.75 (-4.55%)
CGC   3.40 (-7.10%)
F   13.73 (-2.49%)
GE   85.47 (-3.03%)
DIS   95.69 (-3.22%)
AMC   7.33 (-2.40%)
PYPL   79.93 (-0.19%)
PFE   49.57 (+0.73%)
NFLX   281.17 (-1.53%)
QQQ   282.71 (-1.47%)
AAPL   144.22 (-2.63%)
MSFT   241.76 (-2.32%)
META   108.78 (-2.36%)
GOOGL   96.05 (-1.45%)
AMZN   93.95 (+0.58%)
TSLA   182.92 (+0.03%)
NVDA   158.27 (-2.72%)
NIO   10.12 (-0.49%)
BABA   75.88 (+0.50%)
AMD   73.19 (-2.60%)
T   18.82 (-1.57%)
MU   55.75 (-4.55%)
CGC   3.40 (-7.10%)
F   13.73 (-2.49%)
GE   85.47 (-3.03%)
DIS   95.69 (-3.22%)
AMC   7.33 (-2.40%)
PYPL   79.93 (-0.19%)
PFE   49.57 (+0.73%)
NFLX   281.17 (-1.53%)
QQQ   282.71 (-1.47%)
AAPL   144.22 (-2.63%)
MSFT   241.76 (-2.32%)
META   108.78 (-2.36%)
GOOGL   96.05 (-1.45%)
AMZN   93.95 (+0.58%)
TSLA   182.92 (+0.03%)
NVDA   158.27 (-2.72%)
NIO   10.12 (-0.49%)
BABA   75.88 (+0.50%)
AMD   73.19 (-2.60%)
T   18.82 (-1.57%)
MU   55.75 (-4.55%)
CGC   3.40 (-7.10%)
F   13.73 (-2.49%)
GE   85.47 (-3.03%)
DIS   95.69 (-3.22%)
AMC   7.33 (-2.40%)
PYPL   79.93 (-0.19%)
PFE   49.57 (+0.73%)
NFLX   281.17 (-1.53%)
NASDAQ:INCY

Incyte - INCY Stock Forecast, Price & News

$77.83
-0.43 (-0.55%)
(As of 11/28/2022 12:00 AM ET)
Add
Compare
Today's Range
$77.61
$79.00
50-Day Range
$66.18
$78.41
52-Week Range
$63.40
$84.86
Volume
867,858 shs
Average Volume
1.51 million shs
Market Capitalization
$17.32 billion
P/E Ratio
19.80
Dividend Yield
N/A
Price Target
$84.20

Incyte MarketRank™ Forecast

Analyst Rating
Hold
2.13 Rating Score
Upside/​Downside
8.2% Upside
$84.20 Price Target
Short Interest
Healthy
3.16% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-1.19
Upright™ Environmental Score
News Sentiment
0.29mentions of Incyte in the last 14 days
Based on 3 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
55.61%
From $2.14 to $3.33 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.53 out of 5 stars

Medical Sector

293rd out of 1,040 stocks

Commercial Physical Research Industry

9th out of 16 stocks

INCY stock logo

About Incyte (NASDAQ:INCY) Stock

Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in various liquid and solid tumor types; and ICLUSIG, a kinase inhibitor to treat chronic myeloid leukemia and philadelphia-chromosome positive acute lymphoblastic leukemia. Its clinical stage products include ruxolitinib, a steroid-refractory chronic graft-versus-host-diseases (GVHD); itacitinib, which is in Phase II/III clinical trial to treat naïve chronic GVHD; and pemigatinib for treating bladder cancer, cholangiocarcinoma, myeloproliferative syndrome, and tumor agnostic. In addition, the company engages in developing Parsaclisib, which is in Phase II clinical trial for follicular lymphoma, marginal zone lymphoma, and mantel cell lymphoma. Additionally, it develops Retifanlimab that is in Phase II clinical trials for MSI-high endometrial cancer, merkel cell carcinoma, and anal cancer, as well as in Phase II clinical trials for patients with non-small cell lung cancer. It has collaboration agreements with Novartis International Pharmaceutical Ltd.; Eli Lilly and Company; Agenus Inc.; Calithera Biosciences, Inc; MacroGenics, Inc.; Merus N.V.; Syros Pharmaceuticals, Inc.; Innovent Biologics, Inc.; Zai Lab Limited; Cellenkos, Inc.; and Nimble Therapeutics, as well as clinical collaborations with MorphoSys AG and Xencor, Inc. to investigate the combination of tafasitamab, plamotamab, and lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma, and relapsed or refractory follicular lymphoma. The company was incorporated in 1991 and is headquartered in Wilmington, Delaware.

Receive INCY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Incyte and its competitors with MarketBeat's FREE daily newsletter.

INCY Stock News Headlines

Incyte A Buy As Revenue From Opzelura Ramps
Is Incyte Building a Vitiligo Empire? - TheStreet
See More Headlines
Receive INCY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Incyte and its competitors with MarketBeat's FREE daily newsletter.

INCY Company Calendar

Last Earnings
8/03/2021
Today
11/28/2022
Fiscal Year End
12/31/2022
Next Earnings (Estimated)
2/14/2023

Industry, Sector and Symbol

Industry
Commercial physical research
Sub-Industry
Biotechnology
Sector
Medical
Current Symbol
NASDAQ:INCY
CUSIP
45337C10
Employees
2,094
Year Founded
1991

Price Target and Rating

Average Stock Price Forecast
$84.20
High Stock Price Forecast
$108.00
Low Stock Price Forecast
$63.00
Forecasted Upside/Downside
+8.2%
Consensus Rating
Hold
Rating Score (0-4)
2.13
Research Coverage
8 Analysts

Profitability

Net Income
$948.58 million
Pretax Margin
17.07%

Debt

Sales & Book Value

Annual Sales
$2.99 billion
Cash Flow
$2.36 per share
Book Value
$17.07 per share

Miscellaneous

Free Float
183,542,000
Market Cap
$17.32 billion
Optionable
Optionable
Beta
0.70

Social Links


Key Executives

  • Mr. Herve  HoppenotMr. Herve Hoppenot (Age 62)
    Chairman, Pres & CEO
    Comp: $2.36M
  • Ms. Christiana Stamoulis MBA (Age 51)
    Exec. VP & CFO
    Comp: $967.48k
  • Ms. Maria E. PasqualeMs. Maria E. Pasquale (Age 56)
    Exec. VP, Gen. Counsel & Corp. Sec.
    Comp: $867.6k
  • Dr. Barry P. Flannelly M.B.A.Dr. Barry P. Flannelly M.B.A. (Age 64)
    MBA, Pharm.D., Exec. VP & GM of North America
    Comp: $842.85k
  • Dr. Steven H. Stein M.D.Dr. Steven H. Stein M.D. (Age 55)
    Exec. VP & Chief Medical Officer
    Comp: $983.84k
  • Mr. Thomas Tray (Age 44)
    VP of Fin., Chief Accounting Officer & Controller
  • Mr. Michael James Morrissey (Age 58)
    Exec. VP & Head of Global Technical Operations
  • Dr. Dashyant Dhanak Ph.D. (Age 61)
    Exec. VP & Chief Scientific Officer
  • Ms. Christine Chiou
    Head of Investor Relations
  • Ms. Pamela M. Murphy (Age 71)
    VP of Investor Relations & Corp. Communications













INCY Stock - Frequently Asked Questions

Should I buy or sell Incyte stock right now?

8 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Incyte in the last year. There are currently 1 sell rating, 5 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" INCY shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in INCY, but not buy additional shares or sell existing shares.
View INCY analyst ratings
or view top-rated stocks.

What is Incyte's stock price forecast for 2023?

8 Wall Street analysts have issued 12 month price objectives for Incyte's shares. Their INCY share price forecasts range from $63.00 to $108.00. On average, they predict the company's stock price to reach $84.20 in the next twelve months. This suggests a possible upside of 7.9% from the stock's current price.
View analysts price targets for INCY
or view top-rated stocks among Wall Street analysts.

How have INCY shares performed in 2022?

Incyte's stock was trading at $73.40 at the beginning of the year. Since then, INCY shares have increased by 6.3% and is now trading at $78.01.
View the best growth stocks for 2022 here
.

Are investors shorting Incyte?

Incyte saw a decline in short interest in November. As of November 15th, there was short interest totaling 7,040,000 shares, a decline of 15.9% from the October 31st total of 8,370,000 shares. Based on an average daily volume of 1,400,000 shares, the short-interest ratio is currently 5.0 days.
View Incyte's Short Interest
.

When is Incyte's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, February 14th 2023.
View our INCY earnings forecast
.

How were Incyte's earnings last quarter?

Incyte Co. (NASDAQ:INCY) released its quarterly earnings results on Tuesday, August, 3rd. The biopharmaceutical company reported $0.80 earnings per share for the quarter, topping analysts' consensus estimates of $0.54 by $0.26. The biopharmaceutical company had revenue of $705.71 million for the quarter, compared to analysts' expectations of $686.95 million. Incyte had a trailing twelve-month return on equity of 9.04% and a net margin of 26.30%. The company's revenue for the quarter was up 2.6% compared to the same quarter last year. During the same period in the prior year, the firm posted $1.24 earnings per share.
Read the conference call transcript
.

What is Hervé Hoppenot's approval rating as Incyte's CEO?

22 employees have rated Incyte Chief Executive Officer Hervé Hoppenot on Glassdoor.com. Hervé Hoppenot has an approval rating of 80% among the company's employees.

What other stocks do shareholders of Incyte own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Incyte investors own include Puma Biotechnology (PBYI), BioMarin Pharmaceutical (BMRN), (MDVN) (MDVN), First Solar (FSLR), United Airlines (UAL), Dynavax Technologies (DVAX), Micron Technology (MU), (KITE) (KITE), Freeport-McMoRan (FCX) and NVIDIA (NVDA).

What is Incyte's stock symbol?

Incyte trades on the NASDAQ under the ticker symbol "INCY."

Who are Incyte's major shareholders?

Incyte's stock is owned by a variety of retail and institutional investors. Top institutional investors include Vanguard Group Inc. (9.54%), BlackRock Inc. (8.83%), State Street Corp (4.29%), Royal Bank of Canada (4.14%), Renaissance Technologies LLC (2.18%) and Bellevue Group AG (1.23%). Insiders that own company stock include Barry P Flannelly, Bros Advisors Lp Baker, Dashyant Dhanak, Herve Hoppenot, Jonathan Elliott Dickinson, Maria E Pasquale, Maria E Pasquale, Michael James Morrissey, Paul Trower, Paula J Swain, Steven H Stein, Thomas Tray, Vijay K Iyengar, Wendy L Dixon and Yao Wenqing.
View institutional ownership trends
.

How do I buy shares of Incyte?

Shares of INCY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Incyte's stock price today?

One share of INCY stock can currently be purchased for approximately $78.01.

How much money does Incyte make?

Incyte (NASDAQ:INCY) has a market capitalization of $17.36 billion and generates $2.99 billion in revenue each year. The biopharmaceutical company earns $948.58 million in net income (profit) each year or $3.93 on an earnings per share basis.

How many employees does Incyte have?

The company employs 2,094 workers across the globe.

How can I contact Incyte?

Incyte's mailing address is 1801 AUGUSTINE CUT-OFF, WILMINGTON DE, 19803. The official website for the company is www.incyte.com. The biopharmaceutical company can be reached via phone at (302) 498-6700, via email at mbooth@incyte.com, or via fax at 302-425-2750.

This page (NASDAQ:INCY) was last updated on 11/28/2022 by MarketBeat.com Staff